Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMEN-LC05 tusamitamab ravtansine + pembrolizumab ± platinum chemotherapy in CEACAM5+ advanced nonsquamous NSCLC
2023-509115-84-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoints: Incidence of study drug-related dose-limiting toxicities (DLTs) at Cycle 1 and Objective response rate (ORR) in expansion part. Started May 2021; status: completed.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509115-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509115-84-00.